Condition
HHV-8
Total Trials
4
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Recruiting2
Terminated1
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT00092222Phase 2Active Not Recruiting
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
NCT01419561Phase 2Recruiting
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
NCT05081141RecruitingPrimary
HHV8 and Solid Organ Transplantation
NCT00287495Phase 1Terminated
BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma
Showing all 4 trials